New PCR Variants Evaluated for Global Diagnostics of Leishmaniasis
|
By LabMedica International staff writers Posted on 04 Nov 2014 |
|
![Image: Leishmania detection sensitivity – Percentage of positivity in the different hsp70-PCRs (G, F, N, C), evaluated in the total of 98 clinical pre-confirmed cutaneous or visceral leishmaniasis case samples (All) and in different subsets (Bone marrow, Blood/BC[buffy coat], Lymph node, Skin biopsy) (Phot courtesy of Montalvo et al., September 2014, and the journal Diagnostic Microbiology and Infectious Disease).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2014-11-04/MMS-122.jpg "Image: Leishmania detection sensitivity – Percentage of positivity in the different hsp70-PCRs (G, F, N, C), evaluated in the total of 98 clinical pre-confirmed cutaneous or visceral leishmaniasis case samples (All) and in different subsets (Bone marrow, Blood/BC[buffy coat], Lymph node, Skin biopsy) (Phot courtesy of Montalvo et al., September 2014, and the journal Diagnostic Microbiology and Infectious Disease).")
Image: Leishmania detection sensitivity – Percentage of positivity in the different hsp70-PCRs (G, F, N, C), evaluated in the total of 98 clinical pre-confirmed cutaneous or visceral leishmaniasis case samples (All) and in different subsets (Bone marrow, Blood/BC[buffy coat], Lymph node, Skin biopsy) (Phot courtesy of Montalvo et al., September 2014, and the journal Diagnostic Microbiology and Infectious Disease).
A study of three new PCR variants based on the leishmanial hsp70 gene, evaluated directly on clinical samples, has demonstrated the new tools to be globally applicable for Leishmania species-level typing in various geographical, clinical, and sampling contexts.
In the diagnosis of leishmaniasis, identification of the causative Leishmania species is also important for treatment and prognosis, as well as for epidemiology (including documentation of sympatric and imported species), identification of new non-human reservoir hosts, and for establishing the link in cases of treatment failure. Three new PCR variants based on the hsp70 (heat-shock protein 70) gene had recently been developed and validated directly (without the need for culturing) on New World clinical samples from Peru.
Now, an international team, led by Prof. Gert Van der Auwera of the Institute of Tropical Medicine (ITM) at Antwerp (Belgium), has evaluated the performance of these PCRs on a set of 133 pre-confirmed positive or negative clinical samples (42 cutaneous and 56 visceral leishmaniasis patients, and 35 negative cases) – all from Old World countries: Italy, Sudan, Israel, and Tunisia. Samples were retrospective (had been previously collected) and included bone marrow, blood, buffy coat, lymph node aspirates, and lesion biopsies.
Results showed that the three new PCRs were more sensitive than those previously described for hsp70, and their respective restriction fragment length polymorphism (RFLP) analyses were more efficient for species identification. Also, in 79% of the confirmed positive samples, the species could be identified directly from original sample DNA.
The study described by Montalvo AM et al. in the September 2014, issue of the journal Diagnostic Microbiology and Infectious Disease suggests that these PCRs have potential for becoming a global reference method for identification of Leishmania species in clinical specimens.
Related Links:
Institute of Tropical Medicine (ITM) at Antwerp
In the diagnosis of leishmaniasis, identification of the causative Leishmania species is also important for treatment and prognosis, as well as for epidemiology (including documentation of sympatric and imported species), identification of new non-human reservoir hosts, and for establishing the link in cases of treatment failure. Three new PCR variants based on the hsp70 (heat-shock protein 70) gene had recently been developed and validated directly (without the need for culturing) on New World clinical samples from Peru.
Now, an international team, led by Prof. Gert Van der Auwera of the Institute of Tropical Medicine (ITM) at Antwerp (Belgium), has evaluated the performance of these PCRs on a set of 133 pre-confirmed positive or negative clinical samples (42 cutaneous and 56 visceral leishmaniasis patients, and 35 negative cases) – all from Old World countries: Italy, Sudan, Israel, and Tunisia. Samples were retrospective (had been previously collected) and included bone marrow, blood, buffy coat, lymph node aspirates, and lesion biopsies.
Results showed that the three new PCRs were more sensitive than those previously described for hsp70, and their respective restriction fragment length polymorphism (RFLP) analyses were more efficient for species identification. Also, in 79% of the confirmed positive samples, the species could be identified directly from original sample DNA.
The study described by Montalvo AM et al. in the September 2014, issue of the journal Diagnostic Microbiology and Infectious Disease suggests that these PCRs have potential for becoming a global reference method for identification of Leishmania species in clinical specimens.
Related Links:
Institute of Tropical Medicine (ITM) at Antwerp
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Latest Microbiology News
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
Channels
Clinical Chemistry
view channel
Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more
Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read moreMolecular Diagnostics
view channel
AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. Identifying these patients earlier could reduce the costs of ineffective... Read more
New Variant Tracking Option Expands Molecular Residual Disease Monitoring
Molecular residual disease (MRD) testing can detect traces of cancer that persist after treatment or emerge during recurrence. Because circulating tumor DNA (ctDNA) may be present at very low levels, residual... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read morePathology
view channel
AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more
AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
Tempus AI (Chicago, IL, USA) will present findings from a study evaluating an artificial intelligence (AI)-enabled pre-screening panel for advanced non-small cell lung cancer (NSCLC) at the ESMO Congress... Read more
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read moreTechnology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Industry
view channel
Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more
Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. Its progressive effects on memory, thinking, behavior, and daily functioning underscore... Read more